The molecular basis of sulfadoxine-pyrimethamine (SP) resistance lies in a combination of single-nucleotide polymorphisms (SNPs) in two genes coding for Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and P. falciparum dihydropteroate synthase (Pfdhps), targeted by pyrimethamine and sulfadoxine, respectively. The continued use of SP for intermittent preventive treatment in pregnant women in many African countries, despite SP's discontinuation as a first-line antimalarial treatment option due to high levels of drug resistance, may further increase the prevalence of SP-resistant parasites and/or lead to the selection of new mutations. An antimalarial drug resistance surveillance study was conducted in western Kenya between 2010 and 2013. A total of 203 clinical samples from children with uncomplicated malaria were genotyped for SNPs associated with SP resistance. 
T he use of sulfadoxine-pyrimethamine (SP) for the treatment of malaria has been discontinued in many African countries due to high levels of drug resistance, as reviewed in reference 1. However, SP is still used in many countries in Africa for intermittent preventive treatment in pregnant women (IPTp), as there are very few drugs available for safe use in pregnant women (2) . One of the factors that allows the selection and maintenance of parasites with genetic backgrounds conferring drug resistance in a population is drug pressure (3) . Therefore, the continued use of SP can maintain or even increase the prevalence of SP-resistant parasites (4) in a population. Resistance to SP is conferred by the accumulation of single-nucleotide polymorphisms (SNPs) in two genes that code for enzymes involved in the P. falciparum folate metabolism, P. falciparum dihydrofolate reductase (Pfdhfr) and P. falciparum dihydropteroate synthase (Pfdhps), which are targeted by pyrimethamine and sulfadoxine, respectively. At least five mutations in Pfdhfr are thought to confer resistance to pyrimethamine: C50R, N51I, C59R, S108N, and I164L (mutated amino acids are in boldface). Similarly, at least five SNPs in Pfdhps are reported to be involved in resistance to sulfadoxine, including S436A/F, A437G, K540E, A581G, and A613S/T. In Africa, the most commonly observed genotype conferring pyrimethamine resistance is the Pfdhfr triple-mutant genotype C 50 I 51 R 59 N 108 I 164 (reviewed in references 1 and 5), which was recently found at frequencies of as high as 80% in East Africa (6) . The addition of a fourth mutation, I164L, has been shown to lead to a highly resistant phenotype (7, 8) , but this I164L mutation is observed only at a low prevalence in western Kenya (6, 9, 10) . In Pfdhps, two different patterns of resistance have been reported in Africa: the 437G and 540E mutations are commonly reported in East Africa, while in West and Central Africa, the 436A and 437G mutations are common (11) (12) (13) . As reviewed in references 1 and 5, the quintuple-mutant genotype (Pfdhfr C 50 I 51 R 59 N 108 I 164 and Pfdhps S 436 G 437 E 540 A 581 A 613 ) has been associated with resistance to SP in many parts of Africa.
Recent studies in East Africa have reported the emergence of triple Pfdhps mutants involving the addition of an SNP at codon 581 or 613 to the double-mutant A437G/K540E genotype (8, (14) (15) (16) (17) . These additional Pfdhps mutations, A581G or A613S/T, have been reported to be present at a low prevalence in P. falciparum isolates collected from western Kenya (6, 10) . However, a novel mutation at codon 436 (S436H) was found in western Kenya (6, 10) and, to the best of our knowledge, has not been reported elsewhere. This S436H mutation was first reported in samples from pregnant women collected between 2002 and 2008 (10) and more recently in samples from the general population collected between 2008 and 2012 (6) . The acquisition of additional Pfdhfr and Pfdhps mutations by parasites harboring the quintuple-mutant genotype Pfdhfr C 50 I 51 R 59 N 108 I 164 and Pfdhps S 436 G 437 E 540 A 581 A 613 has led to so-called superresistant parasites due to their increased resistance to SP (reviewed by Naidoo and Roper [5] ). Therefore, it is important to continuously monitor the prevalence of resistant mutant genotypes in Africa, where SP is still used for prophylaxis in pregnant women, as previously reviewed by Venkatesan et al. (18) .
Studies on the dynamics of antimalarial drug resistance in Africa have indicated that pyrimethamine-resistant parasites originated from Southeast Asia and subsequently spread to Africa (19) . In addition, a recent study by Mita et al. (20) provided further evidence to suggest that some Pfdhps alleles migrated from Southeast Asia to Africa. Nevertheless, multiple local origins of Pfdhps single-mutant and Pfdhps double-mutant genotypes have also been reported previously (21) . However, our understanding of the geographic origin and spread of sulfadoxine-resistant Pfdhps genotypes is far from complete, as Pfdhps triple-mutant parasites are still evolving in this region. Recently, the A581G mutation, known to confer increased resistance to sulfadoxine, was shown to have a local origination in Malawi and Tanzania (16) . Therefore, the appearance of the additional Pfdhps S436H mutation in western Kenya warrants some investigation into its origin(s). Did it evolve within the S 436 G 437 E 540 A 581 A 613 background, which is almost at fixation in this region, or did it arrive with parasites introduced from elsewhere in Africa or Southeast Asia?
We investigated the prevalence of SNPs associated with SP resistance in P. falciparum isolates collected from children in western Kenya between 2010 and 2013. In addition, the microsatellite allele heterozygosity in the Pfdhps S 436 G 437 E 540 A 581 A 613 double mutant and H 436 G 437 E 540 A 581 A 613 triple mutant was investigated to determine whether this gene may have undergone recent selective pressure. In order to determine the genetic relatedness of the Pfdhps mutants observed in this study, the haplotypes of eight microsatellite loci flanking the Pfdhps locus were determined and compared to the haplotypes of mutant parasites from Cambodia, Ghana, and Thailand.
MATERIALS AND METHODS
Sample collection. The Kenya Medical Research Institute (KEMRI) has initiated a continuous in vitro and molecular surveillance study to monitor the evolving patterns of antimalarial resistance in western Kenya. As part of this surveillance, two public hospitals located in the Siaya and Bondo Districts in western Kenya were used to collect blood samples between 2010 and 2013. These hospitals are located in a region of the country where malaria is endemic, with the prevalence of P. falciparum infection ranging from 20% to 40% (http://www.pmi.gov /docs/default-source/default-document-library/malaria-operational-plans /fy14/kenya_mop_fy14.pdf?sfvrsnϭ10). The two hospitals are approximately 60 km from KEMRI in Kisian, Kenya, where the laboratory studies were conducted. The Bondo District Hospital outpatient department examines up to 50 patients on a single day during peak malaria season. The Siaya District Hospital is the only major hospital serving the Siaya District. The outpatient department examines over 40 patients per day during peak malaria transmission seasons. The aim of the study was to monitor the prevalence of genotypes associated with resistance to different antimalarial drugs. Children between the ages of 6 months and 7 years with a diagnosis of uncomplicated P. falciparum malaria and an axillary temperature of Ն37.5°C or a history of fever in the previous 24 h with no recent treatment (at least in the last 7 days) for malaria were enrolled. This study was approved by the institutional review boards of KEMRI and the Centers for Disease Control and Prevention (CDC). The parents or guardians of all children who met the inclusion criteria were referred by the health facility nurse or clinical officer to study personnel. An informed written consent to participate in the study was obtained from the parent/guardian of the children who participated in this study.
Pfdhfr and Pfdhps genotyping analysis. Genomic DNA was isolated from blood samples collected on Whatman grade 3 filter papers using a QIAamp blood minikit (Qiagen Inc., CA, USA). SNPs at Pfdhfr codons 50, 51, 59, 108, and 164 and Pfdhps codons 436, 437, 540, 581, and 613 were identified using Sanger sequencing as previously described (22) . Sequencing of the nested purified PCR products was performed using a BigDye Terminator (v3.1) cycle sequencing kit on an iCycler thermal cycler (BioRad, Hercules, CA). The DNA from the reaction mixtures was precipitated in 70% ethanol to clean up the dye terminators, rehydrated in 10 l HiDi formamide, and sequenced using an Applied Biosystems 3130 xl sequencer (Life Technologies, Grand Island, NY). The codons were classified as wild type (having only the wild-type codon present in the sample), mutant (having only the mutant codon present in the sample), or mixed (having both wild-type and mutant codons present in the sample). Mixed infections were excluded when genotype calling was done. However, the presence of mixed infections was reported.
Temporal trend in prevalence of major genotypes conferring SP resistance in western Kenya. In order to determine the temporal trends in the prevalence of the major genotypes conferring SP resistance since SP was introduced in western Kenya, historical published data from the same region (10, 23) were used together with data obtained from the current study. In calculating the prevalence of these genotypes, isolates with mutant codons were analyzed together with isolates with mixed genotypes. The previously published prevalence data reported by the authors were extracted from the tables and figures.
Multilocus genotyping and estimating expected heterozygosity. We genotyped eight microsatellite loci flanking Pfdhps on chromosome 8 at Ϫ7.5, Ϫ2.9, Ϫ1.5, Ϫ0.13, 0.03, 0.5, 1.4, and 6.4 kb. The markers with negative values denote loci located 5= (upstream) of Pfdhps, while markers with positive values denote loci located 3= (downstream) of the gene. These loci and their respective primers and cycling conditions have been described previously (21, 24, 25) and have been used to investigate signatures of selection around the Pfdhps gene. Loci that are under selection tend to show a lower expected heterozygosity (H e ) than loci that are selectively neutral (26) . In addition, eight putatively neutral microsatellite loci located on chromosomes 2 and 3 were genotyped in order to exclude the possibility that the samples were infected with multiple strains and to estimate the neutral baseline H e in the samples analyzed (27) . These eight microsatellite loci were as follows: C2M27, C2M29, C2M33, and C2M34 on chromosome 2 and C3M39, C3M40, C3M69, and C3M88 on chromosome 3. The eight neutral microsatellite loci and their respective primers and cycling parameters have been described previously (9, 21, 22, 24) .
The sizes of the amplification products were assayed by capillary electrophoresis on an Applied Biosystems 3130 xl sequencer (Life Technologies, Grand Island, NY). The fragments were then scored using GeneMapper software (v3.7; Life Technologies, Grand Island, NY) with default microsatellite settings, where peaks lower than 100 relative fluorescence units (RFU) were defined to be background peaks. The tallest peak was identified to be the predominant allele; peaks whose height was over 33% of the height of the tallest peak were identified to be additional alleles. When more than one allele was identified at any locus, the sample was presumed to be infected with two or more genetically distinct clones. Samples for which amplification of one or more loci was initially unsuccessful were reanalyzed to complete the microsatellite profiles. Only those samples presumed to be infected by a single parasite clone (defined by amplification of only one allele at each of the eight neutral microsatellite loci and each of the eight loci flanking Pfdhps on chromosome 8) were used for H e analysis (n ϭ 29). H e was estimated for each microsatellite locus using the Excel microsatellite tool kit (28) . We used the following formulae to calculate
where n is the number of samples genotyped for the locus and p i is the frequency of the ith allele.
RESULTS
A total of 203 samples collected during 4 years of continuous surveillance (2010 to 2013) were genotyped for the Pfdhfr and Pfdhps mutations associated with SP resistance. Table 1 summarizes the different SNPs observed in the samples collected during the 4 years of the study. Of the 202 samples successfully genotyped for the Pfdhfr gene, 99.5% harbored the mutant allele 51I, while 1 sample (0.5%) had a mixed infection with both wild-type and mutant parasites at this codon. No mutations were observed at codon 50. One hundred eighty-seven samples (92.6%) had the mutant allele 59R at codon 59, 7 had the wild-type allele at codon 59 (3.5%), and 8 (3.9%) had mixed infections with both wild-type and mutant alleles. All the samples genotyped (100%) harbored the 108N mutation, and 4 samples out of 202 (2%) had the 164L mutation; 2 of the samples with the latter mutation were part of mixed infections with the wild-type allele.
We observed the Pfdhps S436H mutation in 28 of the 198 (14.1%) samples successfully genotyped for this codon; over half of these samples (16 out of 28) also harbored the wild-type allele. The 437G mutation was observed in 100% of the samples genotyped. Similarly, 203 out of 203 samples harbored the 540E mutation, except that 1 of these had a mixed infection with both wild-type and mutant alleles. The Pfdhps A581G mutation was observed in 3 out of 203 samples (1.5%), 2 of which were mixed infections with the wild-type allele. All the samples genotyped harbored the wild-type A613 allele.
The overall frequency of parasites with the Pfdhfr triplemutant C 50 I 51 R 59 N 108 I 164 genotype was 91.7%. The Pfdhfr double-mutant C 50 I 51 C 59 N 108 I 164 genotype was present in 2.6% of samples, and 1% of samples had the quadruple-mutant C 50 I 51 R 59 N 108 L 164 genotype. No wild-type genotypes were detected; however, 4.7% of the isolates had mixed genotypes at codon 51 (n ϭ 1), 59 (n ϭ 7), and/or 164 (n ϭ 2) ( In order to determine the temporal trends in the prevalence of the major genotypes conferring SP resistance since SP was introduced in western Kenya, we plotted the prevalence of these genotypes, as reported from selected published data collected by others in the same region (10, 23) and data obtained from this study (2010 to 2013), against the year in which the data were collected 
a Mutations are in boldface.
( Fig. 1 ). 
FIG 1
Temporal trends over time (including published data from studies conducted by others). The prevalence of the major genotypes conferring SP resistance from selected published data (10, 23) , in addition to those obtained from this study (2010 to 2013), was used to determine the temporal trends of these genotypes since the time that SP was first recommended for use as a first-line treatment for uncomplicated malaria in western Kenya. WT, wild type. only 2.3% of samples in 2012 and 2.1% of samples in 2013 (Fig. 1) . The presence and apparent increase in the prevalence of the Pfdhps H 436 G 437 E 540 A 581 A 613 triple mutant, as previously reported by studies conducted in the same study area (6, 10), prompted us to hypothesize that this gene may have undergone recent selection. Therefore, we amplified the microsatellite alleles flanking the Pfdhps gene to identify potential signatures of selection. The region flanking the Pfdhps gene had very low H e values in parasites with the H 436 G 437 E 540 A 581 A 613 and S 436 G 437 E 540 A 581 A 613 genotypes compared to those for neutral microsatellite loci on chromosomes 2 and 3 ( Fig. 2) , indicating that this gene may have been under some selective pressure immediately prior to or during the time period from 2010 to 2013.
In order to determine the genetic relatedness of the Pfdhps mutants observed in this study, the alleles of 8 microsatellite loci flanking the Pfdhps locus were amplified, and the resulting haplotypes were compared to the haplotypes of mutant parasites from Cambodia and Thailand and a single sample from Ghana. No comparison to Pfdhps wild-type parasites was possible because none of our samples had pure wild-type genotypes. We found that the H 436 G 437 E 540 A 581 A 613 isolates had microsatellite haplotypes identical to those of most S 436 G 437 E 540 A 581 A 613 mutant isolates from western Kenya (Fig. 3) . Additionally, the majority of the double and triple mutants in our study appeared to share an ancestral lineage with parasites from Thailand and Cambodia, given the similarities in their microsatellite haplotypes. The single isolate with the triple-mutant S 436 G 437 E 540 G 581 A 613 genotype from our study had a unique haplotype profile which was different from that of the majority of isolates that we compared (Fig. 3) .
DISCUSSION
Shortly after the introduction of SP as first-line therapy for malaria in Kenya, a sharp decline in the prevalence of the wild-type Pfdhfr and Pfdhps genotypes was observed, and this decline was accompanied by an increase in the prevalence of the Pfdhfr triplemutant and Pfdhps double-mutant genotypes conferring resistance (9) . By early 2000, the prevalence of these genotypes was above 80% (10, 17) , and it has remained high, despite the fact that SP was replaced by artemether-lumefantrine in 2006 as a first-line treatment for uncomplicated malaria (29) . SP is still the drug of choice for IPTp. In addition, it is likely that the use of other sulfa drugs by the general population for the treatment of other illnesses, such as respiratory and diarrheal diseases, may be contributing to the sustained selection pressure (30) . The emergence of Pfdhps triple mutants with the acquisition of the Pfdhps A581G or A613S/T mutation and Pfdhfr quadruple mutants with the acquisition of the I164L mutation has been described in studies conducted in East Africa (8-10, 16, 17, 31) , implying that these genotypes continue to evolve in this region. The presence of the Pfdhfr I164L mutants in western Kenya was first reported by McCollum et al. in 2006 (9) . Several other studies have shown the presence of this mutation, but it was always present at low frequencies (10, 32) . It is surprising that, even about a decade later and despite the continued use of SP for IPTp, our study found only 4 samples out of 202 (2%) harboring this mutation, and 2 of these had mixed infections with the wild-type allele. This slow progression in the evolution of Pfdhfr quadruple mutants in this region may be due to the low level of fitness of this genotype in this area of holoendemicity, as has been speculated by others (33) . The Pfdhps A581G mutation was also found at a low prevalence (1.5%), which is in agreement with the findings of previous studies from western Kenya (6, 10). We did not observe any mutations at codon 613, although previous studies have reported its occurrence at a low prevalence (6, 10, 17) . Interestingly, we observed an increase in the prevalence of the Pfdhps S436H mutation since it was first described in isolates obtained from pregnant women in western Kenya (10) . To date, only parasites collected in western Kenya have been found to harbor this mutation (6, 10) .
While the effect of the S436H mutation on SP resistance is not yet known, it is possible that, like other mutations described at this codon (34) (35) (36) , it may interfere with the efficient binding of sulfadoxine, leading to increased resistance (36) . Therefore, it is important to understand the potential impact of this triple-mutant genotype in increasing the resistance threshold for SP treatment and the effectiveness of SP prophylaxis in pregnant women.
We only at a low prevalence in western Kenya in recent years (6, 10 581 A 613 genotype observed in our study had a unique microsatellite haplotype profile compared to the profiles of the other isolates from Kenya as well as those from Thailand, Cambodia, and Ghana. The possibility of local migration from neighboring countries, such as Tanzania, cannot be ruled out, given that the Pfdhps triple-mutant S 436 G 437 E 540 G 581 A 613 genotype has been reported in this region (8, (15) (16) (17) 37) . However, further studies using more samples are needed to definitively answer this question.
Several studies from East Africa have reported on the decreased efficacy of SP due to the high prevalence of genotypes conferring SP resistance in this region (8, 14, 15, 37, 38) . The use of SP in IPTp was associated with increased placental inflammation and appeared to select for parasites with the Pfdhps 581G allele, which confers high levels of resistance (37) . These studies have raised some concerns about the continued use of SP in IPTp in areas where Pfdhfr triple-mutant genotypes are near fixation. The WHO recommends the discontinuation of SP in IPTp when the prevalence of the Pfdhps A581G mutation is greater than 10% (39) . In addition, a trend toward an increase in the level of the novel H 436 G 437 E 540 A 581 A 613 genotype, whose role in SP resistance remains to be elucidated, shows that the Pfdhps gene continues to evolve. These findings warrant continued vigilance to determine if SP is going to remain efficacious for IPTp in the future in this region.
